PHA-543,613 is a drug that acts as a potent and selective agonist for the α7 subtype of neural nicotinic acetylcholine receptors, with a high level of brain penetration and good oral bioavailability.

It is under development as a possible treatment for cognitive deficits in schizophrenia.

[1] It reduces excitotoxicity[2] and protects striatal dopaminergic neurons in rat models.

[3] It also potentiates cognitive enhancement from memantine,[4][5] decreases dynorphin release[6] and inhibits GSK-B3.

[7]